Literature DB >> 30563749

Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells.

Hillary C Valley1, Katherine M Bukis1, Alisa Bell1, Yi Cheng1, Eric Wong1, Nikole J Jordan1, Normand E Allaire1, Andrey Sivachenko1, Feng Liang1, Hermann Bihler1, Philip J Thomas2, Jerome Mahiou1, Martin Mense3.   

Abstract

BACKGROUND: Assessment of approved drugs and developmental drug candidates for rare cystic fibrosis (CF)-causing variants of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) requires abundant material from relevant models.
METHODS: Isogenic cell lines harboring CFTR variants in the native genomic context were created through the development and utilization of a footprint-less, CRISPR/Cas9 gene editing pipeline in 16HBE14o- immortalized bronchial epithelial cells.
RESULTS: Isogenic, homozygous cell lines for three CFTR variants (F508del and the two most common CF-causing nonsense variants, G542X and W1282X) were established and characterized. The F508del model recapitulates the known molecular pathology and pharmacology. The two models of nonsense variants (G542X and W1282X) are sensitive to Nonsense Mediated mRNA Decay (NMD) and responsive to reference compounds that inhibit NMD and promote ribosomal readthrough.
CONCLUSIONS: We present a versatile, efficient gene editing pipeline that can be used to create CFTR variants in the native genomic context and the utilization of this pipeline to create homozygous cell models for the CF-causing variants F508del, G542X, and W1282X. The resulting cell lines provide a virtually unlimited source of material with specific pathogenic mutations that can be used in a variety of assays, including functional assays.
Copyright © 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR; CRISPR/Cas9; Cystic Fibrosis; Model system; Nonsense mutation; Premature termination codon

Year:  2018        PMID: 30563749     DOI: 10.1016/j.jcf.2018.12.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  34 in total

1.  Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction.

Authors:  Shingo Suzuki; Ana M Crane; Varada Anirudhan; Cristina Barillà; Nadine Matthias; Scott H Randell; Andras Rab; Eric J Sorscher; Jenny L Kerschner; Shiyi Yin; Ann Harris; Matthew Mendel; Kenneth Kim; Lei Zhang; Anthony Conway; Brian R Davis
Journal:  Mol Ther       Date:  2020-04-29       Impact factor: 11.454

Review 2.  One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.

Authors:  Marjolein M Ensinck; Marianne S Carlon
Journal:  Cells       Date:  2022-06-08       Impact factor: 7.666

3.  Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.

Authors:  Nicholas E King; Shingo Suzuki; Cristina Barillà; Finn J Hawkins; Scott H Randell; Susan D Reynolds; Barry R Stripp; Brian R Davis
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

4.  Serum starvation enhances nonsense mutation readthrough.

Authors:  Amnon Wittenstein; Michal Caspi; Yifat David; Yamit Shorer; Prathamesh T Nadar-Ponniah; Rina Rosin-Arbesfeld
Journal:  J Mol Med (Berl)       Date:  2019-11-15       Impact factor: 4.599

Review 5.  Pharmacological approaches for targeting cystic fibrosis nonsense mutations.

Authors:  Jyoti Sharma; Kim M Keeling; Steven M Rowe
Journal:  Eur J Med Chem       Date:  2020-05-21       Impact factor: 6.514

Review 6.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

7.  Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.

Authors:  Onofrio Laselva; Claire Bartlett; Tarini N A Gunawardena; Hong Ouyang; Paul D W Eckford; Theo J Moraes; Christine E Bear; Tanja Gonska
Journal:  Eur Respir J       Date:  2021-06-17       Impact factor: 16.671

8.  Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.

Authors:  Ami M Kabadi; Leah Machlin; Nikita Dalal; Rhianna E Lee; Ian McDowell; Nirav N Shah; Lauren Drowley; Scott H Randell; Timothy E Reddy
Journal:  J Cyst Fibros       Date:  2021-05-25       Impact factor: 5.482

9.  Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.

Authors:  Venkateshwar Mutyam; Jyoti Sharma; Yao Li; Ning Peng; Jianguo Chen; Li Ping Tang; Emily Falk Libby; Ashvani K Singh; Katja Conrath; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

10.  A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.

Authors:  Jyoti Sharma; Ming Du; Eric Wong; Venkateshwar Mutyam; Yao Li; Jianguo Chen; Jamie Wangen; Kari Thrasher; Lianwu Fu; Ning Peng; Liping Tang; Kaimao Liu; Bini Mathew; Robert J Bostwick; Corinne E Augelli-Szafran; Hermann Bihler; Feng Liang; Jerome Mahiou; Josef Saltz; Andras Rab; Jeong Hong; Eric J Sorscher; Eric M Mendenhall; Candice J Coppola; Kim M Keeling; Rachel Green; Martin Mense; Mark J Suto; Steven M Rowe; David M Bedwell
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.